FDA
-
-
-
-
-
-
-
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Announces 739K Share offering at $6.25/sh
-
-
-
-
-
-
-
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Receives FDA Study May Proceed Notice for Phase 2 Trial of TPST-1495
-
-
-
-
-
-
-
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Trial
-
-
-
-
-
-
-
Tempest Therapeutics (TPST) Appoints Troy M. Wagner as VP of Quality Assurance
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

